Korro Bio, Inc. (KRRO) Income Statement
KRRO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKRRO revenue and net income
Where KRRO's revenue goes
2025Each bar shows an amount and its share of revenue. KRRO kept −1,834.5% of revenue as net income.
KRRO profit margins
KRRO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +181.5% | — | −29.6% | — |
| Gross profit | −7.0% | — | −43.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KRRO quarterly EPS vs estimates
Korro Bio beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 11, 2026 (estimate $-1.14).
KRRO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0 | $0 | $14.1M | $37.0M | $28.9M | $0 | $0 |
| Cost of revenue | $4.3M | $3.6M | $3.6M | $2.5M | $3.8M | $1.6M | $16.8M | $654,000 | $531,000 |
| Gross profit | $2.1M | $2.3M | −$3.6M | −$2.5M | $10.2M | $35.4M | $12.1M | −$654,000 | −$531,000 |
| Research & development | $65.6M | $63.6M | $57.2M | $42.2M | $23.8M | $36.7M | $18.3M | $11.6M | $11.8M |
| Sales, general & admin | $28.2M | $30.5M | $24.0M | $16.8M | $11.7M | — | — | — | — |
| Total operating expenses | $89.5M | $94.2M | $84.5M | $59.0M | $35.5M | $63.0M | $32.8M | $18.3M | $15.8M |
| Operating income | −$87.3M | −$91.9M | −$84.5M | −$59.0M | −$35.5M | −$27.6M | −$20.7M | −$18.9M | −$16.3M |
| Interest income | — | — | — | $947,000 | — | — | — | — | — |
| Interest expense | — | — | — | $118,000 | $764,000 | — | — | $106,000 | $174,000 |
| Income before taxes | −$116.6M | −$83.4M | −$81.1M | −$58.0M | −$22.0M | −$26.5M | −$18.7M | −$19.2M | −$20.2M |
| Income taxes | $637,000 | $141,000 | $27,000 | $10,000 | $2,000 | $35,000 | — | — | $1 |
| Net income | −$117.3M | −$83.6M | −$81.2M | −$58.0M | −$22.0M | −$26.5M | −$18.7M | −$19.2M | −$20.2M |
| EBITDA | −$83.1M | −$88.3M | −$80.9M | −$56.5M | −$33.9M | −$24.9M | −$17.9M | −$18.4M | −$19.5M |
| EPS (diluted) | −$8.80 | −$9.39 | −$42.00 | −$2.32 | −$2.47 | −$0.81 | −$1.20 | — | — |
| Gross margin | 33.0% | 100.0% | — | — | 72.7% | 95.7% | 41.9% | — | — |
| Operating margin | −1,366.4% | −4,047.1% | — | — | −252.3% | −74.5% | −71.4% | — | — |
| Net margin | −1,834.5% | −3,680.4% | — | — | −156.1% | −71.7% | −64.8% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.3M | $1.1M | $1.5M | $2.5M | $2.3M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $380,000 | $649,000 | $0 | $0 | $0 | −$1.4M | $865,000 | $721,000 | $726,000 | $1.8M | $919,000 |
| Gross profit | — | −$380,000 | $643,000 | $1.1M | $1.5M | $2.5M | $2.3M | −$865,000 | −$721,000 | −$726,000 | −$1.8M | −$919,000 |
| Research & development | $13.6M | $13.0M | $11.0M | $13.8M | $21.0M | $19.7M | $17.0M | $16.0M | $17.1M | $13.6M | $15.4M | $14.0M |
| Sales, general & admin | $6.5M | $7.5M | $6.2M | $6.5M | $6.9M | $7.8M | $8.3M | $6.4M | $6.1M | $6.9M | $10.1M | $5.1M |
| Total operating expenses | $20.1M | $20.4M | $16.5M | $20.3M | $28.7M | $27.6M | $25.3M | $23.3M | $24.1M | $21.5M | $26.9M | $19.1M |
| Operating income | −$20.1M | −$20.4M | −$15.9M | −$19.2M | −$27.2M | −$25.0M | −$23.0M | −$23.3M | −$24.1M | −$21.5M | −$26.9M | −$19.1M |
| Income before taxes | −$18.8M | −$19.5M | −$49.4M | −$18.1M | −$25.8M | −$23.4M | −$21.1M | −$21.0M | −$21.8M | −$19.5M | −$25.4M | −$18.5M |
| Income taxes | $108,000 | $95,000 | $636,000 | — | $1,000 | — | $103,000 | −$9,000 | $30,000 | $17,000 | $5,000 | −$7,000 |
| Net income | −$18.9M | −$19.6M | −$50.0M | −$18.1M | −$25.8M | −$23.4M | −$21.2M | −$21.0M | −$21.8M | −$19.6M | −$25.4M | −$18.5M |
| EBITDA | −$19.7M | −$20.1M | −$15.2M | −$16.9M | −$26.0M | −$23.8M | −$21.8M | −$22.4M | −$23.4M | −$20.7M | −$25.9M | −$18.2M |
| EPS (diluted) | −$1.07 | −$1.69 | −$1.65 | −$1.92 | −$2.74 | −$2.49 | −$2.26 | −$2.26 | −$2.43 | −$2.44 | −$25.65 | −$15.50 |
| Gross margin | — | — | 49.8% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating margin | — | — | −1,229.3% | −1,764.9% | −1,863.2% | −981.2% | −1,014.5% | — | — | — | — | — |
| Net margin | — | — | −3,873.2% | −1,657.0% | −1,765.1% | −917.1% | −933.5% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KRRO's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KRRO financial results
In fiscal year 2025 (ended December 31, 2025), Korro Bio reported revenue of $6.4 million, up 181.5% from the year before. It had a net loss of $117.3 million, a net profit margin of −1,834.5%. Diluted earnings per share came to −$8.80. Over five years revenue grew at an average rate of −29.6% a year.
See the KRRO stock overview for the latest quote and news, or the KRRO chart for price history and technical indicators.
KRRO income statement FAQ
What is Korro Bio's annual revenue?
Korro Bio reported total revenue of $6.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 181.5% from $2.3 million the previous year.
Is Korro Bio profitable?
No. Korro Bio reported a net loss of $117.3 million in fiscal 2025, a net profit margin of −1,834.5%; its operating margin was −1,366.4%.
What is Korro Bio's gross margin?
Korro Bio's gross margin was 33.0% in fiscal 2025: for every $100 of revenue, Korro Bio kept $33 after the direct cost of its products and services.
How much does Korro Bio spend on research and development?
Korro Bio spent $65.6 million on research and development in fiscal 2025, 1,025.9% of revenue.
How fast is Korro Bio growing?
Revenue grew −29.6% a year on average over the last five fiscal years, from $37.0 million to $6.4 million.
What are Korro Bio's earnings per share?
Korro Bio earned $-8.80 per diluted share in fiscal 2025, compared with $-9.39 a year earlier.
When will Korro Bio report its next earnings?
Korro Bio is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Korro Bio's fiscal year end?
Korro Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.